Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06441747 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

StatusRecruiting
PhasePhase 2
Started2024-09-23
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 6, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.
The aim of this study is to investigate whether the combination of durvalumab and olaparib in the maintenance setting after initial chemotherapy and durvalumab will benefit patients with locally advanced or metastatic cholangiocarcinoma.

Amendment record

Amended 4 times since 2024-05-29; most recent filed 2026-05-05. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-05-05
Amendment Study Status, Contacts/Locations v4
2025-07-27
Amendment Study Status, Contacts/Locations v3
2025-07-07
Amendment Study Status, Contacts/Locations v2
2025-01-13
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
2024-05-29
Original filing
Trial Details
NCT Number NCT06441747
Lead Sponsor Australasian Gastro-Intestinal Trials Group
Collaborators: Wayne Elphinstone Research Fund, AstraZeneca
Conditions Cholangiocarcinoma
Enrollment 40 participants
Start Date 2024-09-23
Primary Completion 2026-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-05-06